Inmed Pharmaceuticals Stock Price Prediction
| INM Stock | USD 1.07 0.04 3.60% |
Momentum 41
Sell Extended
Oversold | Overbought |
Wall Street Target Price 20 | Quarterly Revenue Growth (0.11) |
Using InMed Pharmaceuticals hype-based prediction, you can estimate the value of InMed Pharmaceuticals from the perspective of InMed Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in InMed Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying InMed because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
InMed Pharmaceuticals after-hype prediction price | USD 1.09 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out InMed Pharmaceuticals Basic Forecasting Models to cross-verify your projections. InMed Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of InMed Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in InMed Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of InMed Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
InMed Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting InMed Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on InMed Pharmaceuticals' historical news coverage. InMed Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.05 and 7.00, respectively. We have considered InMed Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
InMed Pharmaceuticals is abnormally volatile at this time. Analysis and calculation of next after-hype price of InMed Pharmaceuticals is based on 3 months time horizon.
InMed Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as InMed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading InMed Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with InMed Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.75 | 5.86 | 0.02 | 0.12 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.07 | 1.09 | 1.87 |
|
InMed Pharmaceuticals Hype Timeline
On the 29th of January InMed Pharmaceuticals is traded for 1.07. The entity has historical hype elasticity of 0.02, and average elasticity to hype of competition of -0.12. InMed is estimated to increase in value after the next headline, with the price projected to jump to 1.09 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 1.87%, whereas the daily expected return is currently at -0.75%. The volatility of related hype on InMed Pharmaceuticals is about 3530.12%, with the expected price after the next announcement by competition of 0.95. The company reported the last year's revenue of 4.94 M. Reported Net Loss for the year was (8.16 M) with profit before taxes, overhead, and interest of 1.62 M. Considering the 90-day investment horizon the next estimated press release will be in about 8 days. Check out InMed Pharmaceuticals Basic Forecasting Models to cross-verify your projections.InMed Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to InMed Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict InMed Pharmaceuticals' future price movements. Getting to know how InMed Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how InMed Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| BDRX | Biodexa Pharmaceticals | 1.55 | 8 per month | 0.00 | (0.04) | 11.45 | (16.09) | 128.35 | |
| GNPX | Genprex | 0.04 | 8 per month | 0.00 | (0.21) | 18.18 | (12.35) | 44.30 | |
| BIVI | Biovie Inc | 0.02 | 8 per month | 0.00 | (0.16) | 6.62 | (7.30) | 19.38 | |
| GLMD | Galmed Pharmaceuticals | 0.11 | 6 per month | 0.00 | (0.14) | 8.04 | (9.20) | 21.39 | |
| GRI | GRI Bio | (0.86) | 4 per month | 0.00 | (0.29) | 11.88 | (20.75) | 77.14 | |
| CNSP | CNS Pharmaceuticals | 0.22 | 7 per month | 0.00 | (0.09) | 7.22 | (7.57) | 26.44 | |
| JAGX | Jaguar Animal Health | (0.01) | 8 per month | 0.00 | (0.07) | 9.71 | (16.87) | 125.57 | |
| ESLA | Estrella Immunopharma | (0.06) | 5 per month | 0.00 | (0.1) | 12.21 | (15.49) | 50.95 | |
| SILO | Silo Pharma | 0.03 | 27 per month | 0.00 | (0.13) | 8.33 | (6.98) | 24.79 | |
| KZIA | Kazia Therapeutics Ltd | (2.70) | 8 per month | 10.05 | 0.05 | 14.69 | (18.36) | 78.79 |
InMed Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine InMed price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for InMed using various technical indicators. When you analyze InMed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About InMed Pharmaceuticals Predictive Indicators
The successful prediction of InMed Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as InMed Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of InMed Pharmaceuticals based on analysis of InMed Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to InMed Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to InMed Pharmaceuticals's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 5.58 | 8.74 | 2.68 | 1.67 | Days Of Inventory On Hand | 129.88 | 108.41 | 3.33 | 3.17 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out InMed Pharmaceuticals Basic Forecasting Models to cross-verify your projections. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Biotechnology sector continue expanding? Could InMed diversify its offerings? Factors like these will boost the valuation of InMed Pharmaceuticals. Market participants price InMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every InMed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.09) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
Understanding InMed Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects InMed's accounting equity. The concept of intrinsic value—what InMed Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push InMed Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InMed Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.